SCHEDULE: Armistice Capital Reports 4.99% Stake in Aethlon Medical

Armistice Capital, LLC and Steven Boyd have jointly reported a beneficial ownership of 4.99% of Aethlon Medical, Inc.'s common stock as of March 31, 2026.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the Reporting Persons, have filed a Schedule 13G, indicating their beneficial ownership of Aethlon Medical, Inc. common stock.
• As of March 31, 2026, the Reporting Persons collectively own 82,410 shares of Aethlon Medical's common stock.
• This ownership stake represents 4.99% of the total class of securities.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, may also be deemed to beneficially own these shares.
• The filing states that the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It indicates a significant investment by Armistice Capital, but without further context on Aethlon Medical's performance or Armistice's intentions, it's neither strongly positive nor negative.

Positives

• Armistice Capital, LLC and Steven Boyd have disclosed a significant ownership stake, indicating confidence or strategic interest in Aethlon Medical, Inc.
• The ownership is below the 5% threshold that would trigger more stringent reporting requirements, suggesting a passive investment approach for now.

Negatives

• The filing does not contain any negative financial results or operational challenges for Aethlon Medical, Inc. itself, as it is a disclosure of ownership by an external entity.

Risks

• The filing does not explicitly mention risks related to Aethlon Medical, Inc. The primary risk is inherent in any investment, which is market volatility and the potential for the stock price to decline.
• The disclaimer from the Master Fund regarding beneficial ownership due to the Investment Management Agreement could introduce complexity in understanding ultimate control.

Future Outlook

The filing does not contain forward-looking statements or guidance from Aethlon Medical, Inc. It is a disclosure of beneficial ownership by an external entity.

Management Comments

• Armistice Capital, LLC exercises voting and investment power over the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

StockSavvy.ai notes that significant stake disclosures by investment firms like Armistice Capital often signal a belief in the target company's potential or an intention to influence corporate strategy. For Aethlon Medical, Inc., this filing suggests external interest in its operations within the medical technology sector.

Stakeholder Impact

• Shareholders: The disclosure may lead to increased investor interest in Aethlon Medical, Inc. due to the significant stake held by Armistice Capital.
• Management of Aethlon Medical, Inc.: May face increased scrutiny or engagement from Armistice Capital regarding corporate strategy and performance.
• Potential Investors: This filing provides information about a significant institutional holder, which can be a factor in investment decisions.

Next Steps

• Armistice Capital, LLC will continue to manage the investment in Aethlon Medical, Inc. on behalf of the Master Fund.
• Further amendments to this Schedule 13G will be filed if there are any changes in beneficial ownership.

Key Dates

Keywords

Aethlon Medical, Schedule 13G, Armistice Capital, Steven Boyd, Beneficial Ownership, Common Stock, SEC Filing, Investment Management